CAPRICOR THERAPEUTICS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 6.2 USD | +9.93% |
|
+14.39% | +26.79% |
| May. 17 | Oppenheimer Initiates Capricor Therapeutics at Outperform Rating | MT |
| May. 13 | Transcript : Capricor Therapeutics, Inc., Q1 2024 Earnings Call, May 13, 2024 |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 6.115 | 70.13 | 70.76 | 95.35 | 150.6 | 177.7 | - | - |
| Enterprise Value (EV) 1 | 6.115 | 70.13 | 70.76 | 95.35 | 150.6 | 177.7 | 177.7 | 177.7 |
| P/E ratio | -0.62 x | -3.9 x | -3.37 x | -3.27 x | -5.89 x | -5.45 x | -24.7 x | 15.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 6.08 x | 226 x | 289 x | 37.4 x | 5.98 x | 6.69 x | 2.26 x | 1.65 x |
| EV / Revenue | 6.08 x | 226 x | 289 x | 37.4 x | 5.98 x | 6.69 x | 2.26 x | 1.65 x |
| EV / EBITDA | -0.79 x | - | -3.38 x | -3.27 x | -6.61 x | -4.15 x | -3.66 x | -4.39 x |
| EV / FCF | - | - | - | - | - | -19.7 x | -4.04 x | -16.2 x |
| FCF Yield | - | - | - | - | - | -5.07% | -24.8% | -6.19% |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 4,777 | 20,448 | 24,149 | 24,703 | 30,793 | 31,503 | - | - |
| Reference price 2 | 1.280 | 3.430 | 2.930 | 3.860 | 4.890 | 5.640 | 5.640 | 5.640 |
| Announcement Date | 3/18/20 | 3/11/21 | 3/10/22 | 3/15/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1.005 | 0.3102 | 0.2449 | 2.551 | 25.18 | 26.58 | 78.61 | 107.9 |
| EBITDA 1 | -7.734 | - | -20.94 | -29.16 | -22.79 | -42.8 | -48.6 | -40.5 |
| EBIT 1 | -7.734 | -13.69 | -20.94 | -29.7 | -23.86 | -34.8 | -5.389 | 14.52 |
| Operating Margin | -769.52% | -4,412.56% | -8,549.79% | -1,163.93% | -94.76% | -130.96% | -6.86% | 13.45% |
| Earnings before Tax (EBT) 1 | -7.642 | -13.66 | -20.02 | -29.02 | -22.29 | -33.65 | -4.923 | 15.1 |
| Net income 1 | -7.642 | -13.66 | -20.02 | -29.02 | -22.29 | -33.65 | -4.923 | 15.1 |
| Net margin | -760.36% | -4,401.94% | -8,175.79% | -1,137.37% | -88.52% | -126.62% | -6.26% | 13.99% |
| EPS 2 | -2.060 | -0.8800 | -0.8700 | -1.180 | -0.8300 | -1.035 | -0.2280 | 0.3640 |
| Free Cash Flow 1 | - | - | - | - | - | -9 | -44 | -11 |
| FCF margin | - | - | - | - | - | -33.86% | -55.97% | -10.19% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 3/18/20 | 3/11/21 | 3/10/22 | 3/15/23 | 2/29/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2020 S1 | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 0.2356 | - | - | - | - | 1.592 | 0.9599 | 2.987 | 3.917 | 6.186 | 12.09 | 4.907 | 4.58 | 4.478 | 12.62 | - |
| EBITDA 1 | - | -4.315 | -6.38 | - | -7.322 | -6.478 | -7.875 | -7.955 | -7.493 | - | -0.7554 | -3.6 | -11.4 | -11.7 | -9.5 | - |
| EBIT 1 | - | -4.315 | -6.38 | - | -7.322 | -6.478 | -8.066 | -8.185 | -7.747 | -6.865 | -1.063 | -10.27 | -10.26 | -10.64 | -0.9503 | -12.1 |
| Operating Margin | - | - | - | - | - | -407% | -840.33% | -274.04% | -197.76% | -110.97% | -8.79% | -209.21% | -224.07% | -237.58% | -7.53% | - |
| Earnings before Tax (EBT) 1 | - | -3.932 | -6.191 | - | -7.109 | -6.371 | -7.721 | -7.768 | -7.367 | -6.391 | -0.7621 | -9.794 | -10.22 | -10.71 | -2.889 | -12.1 |
| Net income 1 | - | -3.932 | -6.191 | - | -7.109 | -6.371 | -7.721 | -7.768 | -7.367 | -6.391 | -0.7621 | -9.794 | -10.22 | -10.71 | -2.889 | -12.1 |
| Net margin | - | - | - | - | - | -400.3% | -804.35% | -260.1% | -188.04% | -103.31% | -6.3% | -199.6% | -223.25% | -239.27% | -22.89% | - |
| EPS 2 | - | -0.1700 | -0.2600 | -0.3200 | -0.2900 | -0.2600 | -0.3100 | -0.3100 | -0.2900 | -0.2500 | -0.0200 | -0.3100 | -0.3225 | -0.3300 | -0.0750 | -0.3100 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/6/20 | 11/9/21 | 3/10/22 | 5/10/22 | 8/10/22 | 11/10/22 | 3/15/23 | 5/11/23 | 8/7/23 | 11/14/23 | 2/29/24 | 5/13/24 | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | - | - | - | - | - | -9 | -44 | -11 |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | 3.36 | - | - | - | - |
| Capex / Sales | - | - | - | 131.68% | - | - | - | - |
| Announcement Date | 3/18/20 | 3/11/21 | 3/10/22 | 3/15/23 | 2/29/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
5.64
USD
Average target price
19.8
USD
Spread / Average Target
+251.06%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +26.79% | 178M | |
| +9.42% | 114B | |
| +11.84% | 104B | |
| -14.15% | 22.41B | |
| -1.05% | 22.28B | |
| -5.29% | 19.07B | |
| -38.29% | 18B | |
| -4.16% | 17.89B | |
| +7.99% | 14.28B | |
| +36.24% | 12.55B |
- Stock Market
- Equities
- CAPR Stock
- Financials Capricor Therapeutics, Inc.